AEZS Zentaris: Company Short-Term Debts

Aeterna Zentaris (AEZS) business relies on launching growth hormone deficiency tests in the US and European markets and developing pharmaceuticals for women. The market valuation visualization on GURU.Markets shows that the metric is 0.00. Aeterna Zentaris (AEZS) generates revenue from the sale of diagnostic systems, as well as through patent licensing and the completion of clinical trial milestones by partners.

To minimize fundamental risks, investors should monitor short-term liabilities, which aggregate all loans and notes with maturities of up to one year. The trend in current borrowings reflects the ability of Aeterna Zentaris (AEZS) to service debt through IP licensing royalties, where low borrowing levels confirm the efficiency of a low-overhead operating model.